Overview

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult subjects with chronic Graft versus Host Disease (cGVHD).
Phase:
Phase 2
Details
Lead Sponsor:
Kadmon Corporation, LLC